Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: A Phase-II controlled trial

Anticancer Research

Volumn 16, Issue 2, 1996, Pages 1001-1004

  Salvati, Franco ^a   Rasi, Guido ^b   Portalone, Luigi ^a   Antilli, Antonio ^a   Garaci, Enrico ^c  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Chemo immunotherapy; IFN ; Ifosfamide; NSCLC; Thymosin 1

Indexed keywords

ALKYLATING AGENT; CD4 ANTIGEN; CD8 ANTIGEN; IFOSFAMIDE; IMMUNOMODULATING AGENT; INTERFERON; RECOMBINANT ALPHA2B INTERFERON; THYMOSIN ALPHA1;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MALE; NATURAL KILLER CELL; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; URINARY TRACT DISEASE;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IFOSFAMIDE; IMMUNITY, CELLULAR; IMMUNOTHERAPY; INTERFERON-ALPHA; LEUKOPENIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; THYMOSIN;

EID: 0030008531     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Johnson DH: Chemotherapy for unresectable non-small cell lung cancer. Semin Oncol 17: 20-29, 1990.
2. Johnson DH: Overview of ifosfamide in small and non-small cell lung cancer. Semin Oncol 17 (suppl 4): 24-30, 1990.
3. Eherhardt W and Niederle N: Ifosfamide in non-small cell lung cancer: A review. Semin Oncol 19 (suppl 7): 40-48, 1992.
4. Dunlap NE, Lane GL, Cloud GA and Tilden AB: In Vitro Natural killer and lymphokine-activated killer activity in patients with bronchogenic carcinoma. Cancer 66: 1499-1504, 1990.
5. Marubayashi M. Solana R, Ramirez R, Aranda E, Galan F, Pena J: Sera from patients with colon, breast and lung cancer induce resistance to lysis mediated by NK cytotoxic factors (NKCF). Br J Cancer 63: 893-846, 1991.
6. Jansen RL, Slingerland R, Goey-SH, Franks CR, Bolhuis RL, Stoter G: Interleukin-2 and interferon-alpha in the treatment of patients with advanced non-small-cell-lung cancer. J Immunother 12: 70-3, 1992.
7. Ardizzoni A, Rosso R, Salvati F, Scagliotti G, Soresi E, Ferrara G, Pennucci C, Baldini E, Cruciani AR, Antilli A: Combination chemotherapy and Interferon alpha 2b in the treatment of advanced non-small cell lung cancer. The Italian Lung Cancer Task Force. Am J Clin Oncol 14: 120-123, 1991.
8. Ardizzoni A, Addamo GF, Baldini E, Conte PF, Soresi E, Portalone L, De Marinis F, Lionetto R, Bruzzi P, Pennucci C, Venturini M, Rosso R, Salvati F: Mitomycin-ifosfamide-platinum (MIP) vs MIP-Interferon (MIP-IFN) vs platinum-carboplatin (CP) in the treatment of metastatic non-small cell lung cancer (NSCLC): results of a FONICAP randomized phase II study. Br J Cancer 71: 115-9, 1995.
9. Goldstein AL, Guha A, Zatz MM, Hardy M, and White A: Purification and biological activity of thymosin, a hormone of the thymus gland. Proc nat Acad Sci (Wash) 69: 1800-1803, 1972.
10. Leichtling KD, Serrate SA and Sztein MB: Thymosin alpha I modulates the expression of high affinity interleukin-2 receptors on normal human lymphocytes. Int J Immunopharmacol 1990, 12, 19-29.
11. Favalli C, Jezzi T, Mastino A, Rinaldi-Garaci C, Riccardi C, Garaci E: Modulation of natural killer activity by thymosin alpha I and interferon. Cancer Immunol Immunother 20: 189-195, 1985.
12. Favalli C, Mastino A, Jezzi T, Grelli S, Goldstein AL, Garaci E: Synergistic effect of thymosin alpha I and alpha-beta interferon on NK activity in tumor hearing mice. Int J Immunopharm 11: 443, 1989.
13. Garaci E, Pica F, Mastino A, Palamara AT, Belardelli F, and Favalli C: Anti-tumor effect of thymosin al/interleukin-2 or thymosin al/interferon ab, following cyclophosphamide, in mice injected with higly metastatic Friend erythroleukemia cells. J Immunother 13: 7-17, 1993.
14. Rasi, G, Silecchia GF, Sinibaldi-Vallebona P, Spaziani E, Pierimarchi P, Sivilia M, Tremiterra S and Garaci E: Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats. Int J Cancer 57: 1-5, 1994.
15. Le Chevalier T, Pastran Z, Subirana R, et al: Phase II study of high-dose ifosfamide plus mesna in advanced non-small cell lung carcinoma. Proceedings of the Ivth European Conference on Clinical Oncology and Cancer Nursing, Madrid, Spain, 1987, p23 (abstr).